{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:30:48Z","timestamp":1777926648049,"version":"3.51.4"},"reference-count":104,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clml.2024.03.006","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T16:54:53Z","timestamp":1710780893000},"page":"573-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-154X","authenticated-orcid":false,"given":"Michael J.","family":"Hochman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4609","authenticated-orcid":false,"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2024.03.006_bib0001","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0002","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11899-014-0234-1","article-title":"Stopping higher-risk myelodysplastic syndrome in its tracks","volume":"9","author":"Pollyea","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"10.1016\/j.clml.2024.03.006_bib0003","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.03.006_bib0004","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/cncr.34119","article-title":"Kantarjian HM Time to blur the blast boundaries","volume":"128","author":"DiNardo","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2024.03.006_bib0005","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/ijms24055018","article-title":"Understanding the continuum between high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"24","author":"Zavras","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clml.2024.03.006_bib0006","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.clml.2024.03.006_bib0007","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0008","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/ajh.26858","article-title":"Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements","volume":"98","author":"Siddiqui","year":"2023","journal-title":"American J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2024.03.006_bib0009","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1200\/JCO.22.02680","article-title":"What is in a name? Consequences of the classification schism in hematopathology","volume":"41","author":"Aster","year":"2023","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.clml.2024.03.006_bib0010","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ajh.26503","article-title":"Classification of myeloid neoplasms\/acute leukemia: global perspectives and the international consensus classification approach","volume":"97","author":"Arber","year":"2022","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2024.03.006_bib0011","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0012","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2024.03.006_bib0013","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0014","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/jha2.791","article-title":"Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions","volume":"4","author":"Patel","year":"2023","journal-title":"EJHaem"},{"issue":"2","key":"10.1016\/j.clml.2024.03.006_bib0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN Guidelines\u00ae Insights: Myelodysplastic Syndromes, Version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.clml.2024.03.006_bib0016","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0017","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","article-title":"Time-dependent changes in mortality and transformation risk in MDS","volume":"128","author":"Pfeilst\u00f6cker","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.03.006_bib0018","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.clml.2024.03.006_bib0019","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2352-3026(22)00352-0","article-title":"On the basis of sex: outcomes in myelodysplastic syndromes","volume":"10","author":"Hochman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.03.006_bib0020","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(22)00323-4","article-title":"A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study","volume":"10","author":"Maggioni","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2024.03.006_bib0021","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2023.01.007","article-title":"Sex disparities in myelodysplastic syndromes: genotype, phenotype, and outcomes","volume":"23","author":"Tinsley-Vance","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"33","key":"10.1016\/j.clml.2024.03.006_bib0022","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"15","key":"10.1016\/j.clml.2024.03.006_bib0024","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0025","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-023-01831-1","article-title":"Risk prediction in MDS: independent validation of the IPSS-M: ready for routine?","volume":"37","author":"Baer","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0026","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41375-023-01910-3","article-title":"Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes","volume":"37","author":"Aguirre","year":"2023","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.clml.2024.03.006_bib0027","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood.2022018896","article-title":"Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes","volume":"141","author":"Kewan","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0028","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-023-01855-7","article-title":"MDS subclassification-do we still have to count blasts?","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.clml.2024.03.006_bib0029","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.03.006_bib0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.03.006_bib0031","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.03.006_bib0032","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13207","article-title":"Molecular pathogenesis of myelodysplastic syndromes with deletion 5q","volume":"102","author":"hoon","year":"2019","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.03.006_bib0033","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2024.03.006_bib0034","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2024.03.006_bib0035","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.2023020331","article-title":"PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy","volume":"142","author":"Miller","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.006_bib0036","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.clml.2024.03.006_bib0037","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.seminoncol.2005.07.008","article-title":"Epigenetic therapy of cancer with 5-aza-2\u2019-deoxycytidine (decitabine)","volume":"32","author":"Momparler","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2024.03.006_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00119","article-title":"Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence","volume":"3","author":"Nazha","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0039","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2024.03.006_bib0040","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.006_bib0041","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s13287-018-1013-z","article-title":"Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival","volume":"9","author":"Corradi","year":"2018","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0042","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/leu.2017.326","article-title":"Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS","volume":"32","author":"Mei","year":"2018","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.clml.2024.03.006_bib0043","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1182\/bloodadvances.2022008268","article-title":"The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression","volume":"7","author":"Kfoury","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.03.006_bib0044","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.2022018512","article-title":"Haplodeficiency of the 9p21 tumor suppressor locus causes myeloid disorders driven by the bone marrow microenvironment","volume":"142","author":"Feng","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.03.006_bib0045","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","article-title":"Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia","volume":"19","author":"Zambetti","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"17","key":"10.1016\/j.clml.2024.03.006_bib0046","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152673","article-title":"Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia","volume":"132","author":"Mei","year":"2022","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0047","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(22)00138-7","article-title":"Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?","volume":"9","author":"Hochman","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.03.006_bib0048","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/leu.2013.193","article-title":"Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells","volume":"27","author":"Geyh","year":"2013","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.clml.2024.03.006_bib0049","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1182\/blood-2011-03-343467","article-title":"Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts","volume":"118","author":"Blau","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.03.006_bib0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.leukres.2004.06.011","article-title":"Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization","volume":"29","author":"Flores-Figueroa","year":"2005","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0051","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/leu.2008.361","article-title":"Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q\u2212 syndrome","volume":"23","author":"Lopez-Villar","year":"2009","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.clml.2024.03.006_bib0052","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2024.03.006_bib0053","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1182\/bloodadvances.2023011578","article-title":"Effects of IL-1\u03b2 inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial","volume":"7","author":"Woo","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2024.03.006_bib0054","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-21-4498","article-title":"FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2024.03.006_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0081-8","article-title":"Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?","volume":"8","author":"Zeidan","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2024.03.006_bib0056","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0057","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","article-title":"A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial","volume":"98","author":"Gore","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2024.03.006_bib0058","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.03.006_bib0059","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1080\/10428194.2020.1869959","article-title":"Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis","volume":"62","author":"Stein","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.03.006_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100791","article-title":"Current and emerging strategies for management of myelodysplastic syndromes","volume":"48","author":"Saygin","year":"2021","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0061","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2024.03.006_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2024.03.006_bib0063","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","article-title":"Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia","volume":"107","author":"Gangat","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2024.03.006_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00744-z","article-title":"Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome","volume":"12","author":"Komrokji","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2024.03.006_bib0065","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.clml.2024.03.006_bib0066","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.03.006_bib0067","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2022-163841","article-title":"Prolonged survival in bi-allelic TP53-mutated (TP53mut) MDS subjects treated with oral decitabine\/cedazuridine in the ascertain trial (ASTX727-02)","volume":"140","author":"Savona","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.006_bib0068","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.006_bib0069","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.03.006_bib0070","article-title":"FDA approves ivosidenib for myelodysplastic syndromes","year":"2023","journal-title":"FDA"},{"issue":"10","key":"10.1016\/j.clml.2024.03.006_bib0071","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2024.03.006_bib0072","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0073","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"16","key":"10.1016\/j.clml.2024.03.006_bib0074","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2024.03.006_bib0075","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(23)00090-X","article-title":"CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study","volume":"10","author":"Peterlin","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.03.006_bib0076","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood-2023-186777","article-title":"Venetoclax and azacytidine treatment for high risk myelodysplastic syndromes and chronic myelomonocytic leukemia as a bridge therapy to transplant. A GESMD study","volume":"142","author":"Zugasti","year":"2023","journal-title":"Blood"},{"issue":"10423","key":"10.1016\/j.clml.2024.03.006_bib0077","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"issue":"30","key":"10.1016\/j.clml.2024.03.006_bib0078","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","volume":"39","author":"Kr\u00f6ger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.03.006_bib0079","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.03.006_bib0080","unstructured":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndromes (MDS) (CAG-00415R). National Coverage Analysis (NCA) Decision Memo. 2024. Accessed: April 3, 2024. Available at: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&NCAId=312+."},{"key":"10.1016\/j.clml.2024.03.006_bib0081","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/blood-2023-187247","article-title":"Favorable outcomes for high-risk MDS and oligoblastic AML with MDS-related changes with reduced intensity allogeneic bone marrow transplantation with post-transplantation cyclophosphamide","volume":"142","author":"Sinanidis","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.03.006_bib0082","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01159","article-title":"Patient-specific measurable residual disease markers predict outcome in patients with myelodysplastic syndrome and related diseases after hematopoietic stem-cell transplantation","author":"Tobiasson","year":"2024","journal-title":"JCO"},{"issue":"14","key":"10.1016\/j.clml.2024.03.006_bib0083","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.03.006_bib0084","first-page":"1289","article-title":"Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes","volume":"109","author":"Escure","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2024.03.006_bib0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.03.006_bib0086","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"16","key":"10.1016\/j.clml.2024.03.006_bib0087","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.03.006_bib0088","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.clml.2024.03.006_bib0089","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.03.006_bib0090","unstructured":"Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS), Aprea Therapeutics. Accessed: January 7, 2024. Available at: https:\/\/ir.aprea.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3\/."},{"issue":"17","key":"10.1016\/j.clml.2024.03.006_bib0091","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ad\u00e8s","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.03.006_bib0092","unstructured":"Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial. Accessed: January 7, 2024. Available at: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2021\/takeda-provides-update-on-phase-3-panther-pevonedistat-3001-trial\/."},{"issue":"15","key":"10.1016\/j.clml.2024.03.006_bib0093","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.clml.2024.03.006_bib0094","unstructured":"Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS. Accessed: January 7, 2024. Available at: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2023\/7\/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds."},{"issue":"11","key":"10.1016\/j.clml.2024.03.006_bib0095","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/cncr.28631","article-title":"Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes","volume":"120","author":"Steensma","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.03.006_bib0096","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2352-3026(22)00265-4","article-title":"Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.clml.2024.03.006_bib0097","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1158\/1078-0432.CCR-22-3348","article-title":"Considerations for drug development in myelodysplastic syndromes","volume":"29","author":"Sekeres","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2024.03.006_bib0098","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac019","article-title":"Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor","volume":"2","author":"Schwartz","year":"2022","journal-title":"Immunother Adv"},{"issue":"1","key":"10.1016\/j.clml.2024.03.006_bib0099","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.03.006_bib0100","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2023-180765","volume":"142","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.03.006_bib0101","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.03.006_bib0102","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/bloodadvances.2022008806","article-title":"Targeting RARA overexpression with tamibarotene, a potent and selective RAR\u03b1 agonist, is a novel approach in AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2024.03.006_bib0103","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/2159-8290.CD-17-0399","article-title":"Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RAR\u03b1 dependency targetable by SY-1425, a potent and selective RAR\u03b1 agonist","volume":"7","author":"McKeown","year":"2017","journal-title":"Cancer Discov"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.03.006_bib0104","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2022-159774","article-title":"Phase 1 results of the first-in-class CXCR1\/2 inhibitor SX-682 in patients with hypomethylating agent failure myelodysplastic syndromes","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:28:08Z","timestamp":1724473688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2152265024001137"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}